Pamela Esposito sold $218k of KYMR
director at Kymera Therapeutics, Inc.. 2,500 shares at an average of $87.31, traded Feb 20, 2026, filed Feb 20, 2026.
Score components
- +15RoleDirector
- +12Trade size$218k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.9%, 3m -9.7%, 6m +37.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-061686, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | MOption exercise Common Stock10b5-1 | +2,500 | $49.10 | $123k | 2,500 | Feb 20, 2026 |
| Feb 20, 2026 | SOpen-market sale Common Stock10b5-1 | -1,900 | $87.06 | $165k | 600 | Feb 20, 2026 |
| Feb 20, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $88.10 | $53k | 0 | Feb 20, 2026 |
| Feb 20, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 2,500 | Feb 20, 2026 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $6.0M 50,000 shares | -7% | |
| 26Weak | Kymera Therapeutics, Inc. | Noah Goodman Chief Business Officer | $387k 3,389 shares | -7% | |
| 32Weak | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $8.9M 77,109 shares | -24% | |
| 35Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $9.2M 80,000 shares | -11% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $8.3M 76,650 shares | -3% | |
| 40Moderate | Kymera Therapeutics, Inc. | Bruce Booth director | $56M 513,245 shares | -18% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $3.4M 31,283 shares | -1% | |
| 75Notable | Kymera Therapeutics, Inc. | Bvf Partners L P/il director, other | $174M 1,630,658 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.